DaVita (DaVita) Research & Development

: $0 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Research & Development is the aggregate amount of research and development expenses during the year. DaVita's Research & Development for the three months ended in Dec. 2023 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was $0 Mil.

DaVita Research & Development Historical Data

The historical data trend for DaVita's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Research & Development

DaVita Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Research & Development																-	-	-	-	-

DaVita Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

DaVita (NYSE:DVA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

DaVita Research & Development Related Terms

Thank you for viewing the detailed overview of DaVita's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita (DaVita) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

TRL:Germany TRL:Germany DVAI34:Brazil

Address

2000 16th Street, Denver, CO, USA, 80202

Website

https://www.davita.com

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,000 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives about two thirds of U.S. sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Executives

Christopher Michael Berry	officer: Chief Accounting Officer	C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Kathleen Alyce Waters	officer: Chief Legal Officer	C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Wendy Lee Schoppert	director	6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale	director
Javier Rodriguez	officer: Chief Executive Officer, DKC	601 HAWAII ST., EL SEGUNDO CA 90245
Barbara J Desoer	director	CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty	officer: Chief Compliance Officer	2000 16TH STREET, DENVER CO 80202
Charles Berg	director, officer: Executive Chair, DMG	48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra	director	1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Michael David Staffieri	officer: Chief Operating Officer, DKC	2000 16TH STREET, DENVER CO 80202
Jason M. Hollar	director	3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price	director	ONE CVS DRIVE, WOONSOCKET RI 02895
Pamela M Arway	director	601 HAWAII ST., EL SEGUNDO CA 90245
Gregory J. Moore	director	130 EAST RANDOLPH STREET, SUITE 1000, CHICAGO IL 60601